Efficacy and safety of immunotherapy in real-world patients with advanced non-small cell lung cancer

Q3 Medicine
Na Yin , Ruihan Yang, Xiangliang Liu, Xiao Chen
{"title":"Efficacy and safety of immunotherapy in real-world patients with advanced non-small cell lung cancer","authors":"Na Yin ,&nbsp;Ruihan Yang,&nbsp;Xiangliang Liu,&nbsp;Xiao Chen","doi":"10.1016/j.ctarc.2025.100908","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to explore the predictors of immunotherapy efficacy for advanced non-small cell lung cancer (NSCLC) in the real world and to analyze the clinical efficacy and safety of patients receiving immunotherapy for advanced NSCLC.</div></div><div><h3>Methods</h3><div>Clinical pathological data from patients diagnosed with advanced NSCLC treated with immune checkpoint inhibitors (ICIs) were collected. Survival analysis and differential efficacy comparison of progression-free survival (PFS) was performed using the Kaplan-Meier method and Log-rank test. Univariate and multivariate analyses of PFS and objective response rate (ORR) were performed by Cox proportional risk regression models and logistic regression models to explore influence factors associated with the prognosis of immunotherapy.</div></div><div><h3><strong>Results</strong></h3><div>(1) Overall, the median PFS (median PFS, mPFS) for 237 patients was 11.3 months (range: 8.5-14.1), the ORR was 55.7 %. Univariate and multivariate analyses of PFS in the overall population found that age ≥65 years, Eastern Cooperative Oncology Group (ECOG) physical status (PS) score of 0-1, clinical stage III, absence of liver metastases, immunotherapy combined with chemotherapy and prognostic nutritional index (PNI) ≥47.8 were independent predictors of longer PFS in immunotherapy-advanced NSCLC. Univariate and multifactorial logistic regression analysis of ORR in 237 patients suggested that ECOG PS score, number of ICI lines and prognostic nutritional index (PNI) were independent influence factors of ORR.</div><div>(2) In the \"stage IV, first-line, ECOG PS 0-1\" subgroup, 106(106/237)patients had an mPFS of 10.9 months (range: 9.6-12.2) and an ORR of 59.4 %. Univariate and multivariate analyses of PFS in subgroups found that liver metastases, immunotherapy combined with chemotherapy and PNI were independent influencers of PFS. A univariate analysis of ORR found that only High-PNI was associated with longer PFS.</div><div>(3) Additional factors affecting the efficacy were explored. A subgroup analysis among 64 (64/237) patients with accessible programmed death-ligand 1 (PD-L1) expression levels showed a trend towards a PFS benefit in patients with PD-L1 tumor cell proportion score (TPS) ≥ 50 % and TPS &lt; 1 % compared to patients with PD-L1 TPS &lt; 1 % (p=0.196); A subgroup analysis among 91 (91/237) patients with traceable genetic test results showed that patients with positive driver genes (KRAS/MET/RET/HER2/EGFR/ALK) had a shorter PFS than patients with negative driver genes (HR=1.712, 95 % CI: 0.994-2.947, p=0.048); Subgroup analyses of efficacy assessment showed significantly prolonged PFS in patients with an initial or best outcome assessment of complete response (CR) or partial remission (PR) compared with stable disease (SD) or progressive disease (PD) (P &lt; 0.001).</div><div>(4) Immune-related adverse events (irAEs) requiring pharmacological intervention or discontinuation were recorded. 61 (61/237) patients experienced irAEs during treatment. Grade 1∼2 adverse reactions occurred in 27.8 % of patients and grade ≥3 adverse reactions in 3.8 % of patients. There was no statistical difference in the occurrence (P=0.728) and severity (P=0.612) of adverse events between the ICIs.</div></div><div><h3>Conclusion</h3><div>This study reports the practical experience of ICIs in the treatment of NSCLC in China by analyzing the efficacy and safety of real-world advanced NSCLC treated with ICIs. The results were generally consistent with those of clinical trials, and the factors with the greatest impact on the efficacy of ICIs were ECOG PS, clinical stage, and PNI. Therefore, physicians can predict the future benefit of immunotherapy for NSCLC based on clinical prognostic indicators and make individualized treatment choices.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100908"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000450","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

The aim of this study was to explore the predictors of immunotherapy efficacy for advanced non-small cell lung cancer (NSCLC) in the real world and to analyze the clinical efficacy and safety of patients receiving immunotherapy for advanced NSCLC.

Methods

Clinical pathological data from patients diagnosed with advanced NSCLC treated with immune checkpoint inhibitors (ICIs) were collected. Survival analysis and differential efficacy comparison of progression-free survival (PFS) was performed using the Kaplan-Meier method and Log-rank test. Univariate and multivariate analyses of PFS and objective response rate (ORR) were performed by Cox proportional risk regression models and logistic regression models to explore influence factors associated with the prognosis of immunotherapy.

Results

(1) Overall, the median PFS (median PFS, mPFS) for 237 patients was 11.3 months (range: 8.5-14.1), the ORR was 55.7 %. Univariate and multivariate analyses of PFS in the overall population found that age ≥65 years, Eastern Cooperative Oncology Group (ECOG) physical status (PS) score of 0-1, clinical stage III, absence of liver metastases, immunotherapy combined with chemotherapy and prognostic nutritional index (PNI) ≥47.8 were independent predictors of longer PFS in immunotherapy-advanced NSCLC. Univariate and multifactorial logistic regression analysis of ORR in 237 patients suggested that ECOG PS score, number of ICI lines and prognostic nutritional index (PNI) were independent influence factors of ORR.
(2) In the "stage IV, first-line, ECOG PS 0-1" subgroup, 106(106/237)patients had an mPFS of 10.9 months (range: 9.6-12.2) and an ORR of 59.4 %. Univariate and multivariate analyses of PFS in subgroups found that liver metastases, immunotherapy combined with chemotherapy and PNI were independent influencers of PFS. A univariate analysis of ORR found that only High-PNI was associated with longer PFS.
(3) Additional factors affecting the efficacy were explored. A subgroup analysis among 64 (64/237) patients with accessible programmed death-ligand 1 (PD-L1) expression levels showed a trend towards a PFS benefit in patients with PD-L1 tumor cell proportion score (TPS) ≥ 50 % and TPS < 1 % compared to patients with PD-L1 TPS < 1 % (p=0.196); A subgroup analysis among 91 (91/237) patients with traceable genetic test results showed that patients with positive driver genes (KRAS/MET/RET/HER2/EGFR/ALK) had a shorter PFS than patients with negative driver genes (HR=1.712, 95 % CI: 0.994-2.947, p=0.048); Subgroup analyses of efficacy assessment showed significantly prolonged PFS in patients with an initial or best outcome assessment of complete response (CR) or partial remission (PR) compared with stable disease (SD) or progressive disease (PD) (P < 0.001).
(4) Immune-related adverse events (irAEs) requiring pharmacological intervention or discontinuation were recorded. 61 (61/237) patients experienced irAEs during treatment. Grade 1∼2 adverse reactions occurred in 27.8 % of patients and grade ≥3 adverse reactions in 3.8 % of patients. There was no statistical difference in the occurrence (P=0.728) and severity (P=0.612) of adverse events between the ICIs.

Conclusion

This study reports the practical experience of ICIs in the treatment of NSCLC in China by analyzing the efficacy and safety of real-world advanced NSCLC treated with ICIs. The results were generally consistent with those of clinical trials, and the factors with the greatest impact on the efficacy of ICIs were ECOG PS, clinical stage, and PNI. Therefore, physicians can predict the future benefit of immunotherapy for NSCLC based on clinical prognostic indicators and make individualized treatment choices.
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信